The History of the International Kidney Cancer Coalition

​

The International Kidney Cancer Coalition was established in response to the growing recognition that people affected by kidney cancer needed a stronger international voice. While advances in medical research had significantly improved understanding of kidney cancer and expanded treatment options, patients and families continued to face challenges accessing reliable information, specialist care, clinical trials, supportive services, and opportunities to influence healthcare policy.

​

Patient organizations from different countries recognised that many of these challenges were shared regardless of national healthcare systems. By working together internationally, they could exchange knowledge, advocate more effectively, support research, and improve access to information for people living with kidney cancer. This collaborative vision led to the formation of the International Kidney Cancer Coalition, creating a global alliance dedicated to representing the interests of kidney cancer patients and their families.

​

Today, IKCC brings together patient organizations from across Europe, North America, South America, Asia, Africa, and Oceania, creating one of the largest international networks dedicated to kidney cancer advocacy. Through collaboration between member organizations, healthcare professionals, researchers, policymakers, industry partners, and international healthcare institutions, the Coalition has helped strengthen awareness, improve patient engagement, promote shared decision-making, and encourage greater collaboration across the global kidney cancer community.

​

Although the majority of IKCC's work focuses on adult kidney cancers, particularly renal cell carcinoma, its broader commitment to improving patient-centred care, health equity, education, survivorship, and international collaboration provides valuable lessons that extend across the wider kidney cancer landscape, including rare pediatric kidney cancers such as Wilms tumor.

​

IKCC's Mission and Vision

​

The International Kidney Cancer Coalition believes that every person affected by kidney cancer should have access to the highest possible standard of care, regardless of where they live. Its mission is to improve outcomes by empowering patients and families through education, advocacy, collaboration, research engagement, and healthcare system improvement while ensuring that patient experiences remain central to future developments in kidney cancer care.

Rather than focusing solely on treatment, IKCC promotes a comprehensive approach that recognises the importance of supporting patients throughout every stage of their journey—from diagnosis and treatment through survivorship, rehabilitation, and long-term quality of life.

​

Its work is guided by several strategic priorities:

​

• Strengthening the global kidney cancer patient voice.

• Improving patient education and health literacy.

• Supporting informed and shared decision-making.

• Promoting evidence-based care.

• Encouraging international research collaboration.

• Supporting clinical trial awareness.

• Reducing inequalities in kidney cancer care.

• Improving access to specialist treatment.

• Advancing survivorship and quality of life.

• Supporting healthcare professional education.

• Promoting healthcare policy development.

• Encouraging collaboration between patient organizations worldwide.

 

These priorities recognise that improving outcomes requires strong partnerships between patients, families, healthcare professionals, researchers, governments, and advocacy organisations working together to achieve common goals.

​

Why the International Kidney Cancer Coalition Matters for Wilms Tumor

​

At first glance, an organisation primarily focused on adult kidney cancer may appear to have limited relevance for children diagnosed with Wilms tumor. However, many of the principles that underpin IKCC's work are equally important within pediatric oncology.

​

Children with Wilms tumor, like adults with kidney cancer, benefit from healthcare systems that prioritise early diagnosis, multidisciplinary care, patient education, access to specialist expertise, evidence-based treatment, survivorship planning, and meaningful engagement between healthcare professionals and families. International collaboration also plays a critical role in advancing research, improving standards of care, and reducing inequalities in access to treatment.

​

IKCC's emphasis on patient advocacy provides an important example of how informed and empowered patients can help shape healthcare policy and improve services. While young children cannot advocate for themselves, parents and caregivers become their strongest advocates throughout diagnosis, treatment, and survivorship. Supporting these families with trusted information, emotional support, and opportunities to participate in healthcare decisions is fundamental to achieving the best possible outcomes.

​

There are also increasing opportunities for collaboration between adult and pediatric kidney cancer communities in areas such as survivorship, psychosocial support, patient education, precision medicine, genomics, rare disease research, digital health, and global health policy. Although the diseases differ biologically, sharing knowledge across specialties encourages innovation and strengthens kidney cancer care as a whole.

​

The Wilms Cancer Foundation contributes to this broader vision by ensuring that pediatric kidney cancer remains visible within international discussions about kidney cancer advocacy and education. Through collaboration with healthcare professionals, patient organizations, researchers, and international partners, the Foundation works to bridge the gap between pediatric and adult kidney cancer communities while remaining firmly focused on the unique needs of children and families affected by Wilms tumor.

​

​​

​

Global Advocacy, Patient Empowerment, Research Collaboration & International Education

​

Global Kidney Cancer Advocacy

​

Since its establishment, the International Kidney Cancer Coalition has become one of the world's leading advocates for people affected by kidney cancer. Working through an international network of patient organizations, healthcare professionals, researchers, policymakers, and partner organisations, IKCC seeks to ensure that every person diagnosed with kidney cancer has access to high-quality healthcare, evidence-based information, supportive services, and opportunities to participate in decisions that affect their care.

​

Advocacy extends well beyond raising awareness. IKCC works to strengthen healthcare policy, improve patient access to specialist services, encourage earlier diagnosis, promote equitable access to innovative treatments, support research, and ensure that patient experiences remain central to healthcare planning. By bringing together organisations from countries with diverse healthcare systems, the Coalition facilitates the exchange of ideas, identifies common challenges, and promotes solutions that can improve kidney cancer care worldwide.

​

Although IKCC primarily represents adults with kidney cancer, many of these advocacy priorities also benefit the wider kidney cancer community. Children diagnosed with Wilms tumor and their families similarly depend on timely diagnosis, multidisciplinary care, clear communication, equitable access to treatment, and comprehensive survivorship services. The principles of patient advocacy promoted by IKCC therefore have broad relevance across both adult and pediatric kidney cancers.

​

IKCC's advocacy work encompasses:

​

• Improving patient access to specialist kidney cancer care.

• Promoting evidence-based treatment.

• Strengthening healthcare policy.

• Encouraging equitable access to medicines.

• Supporting patient participation in healthcare decisions.

• Expanding education and awareness.

• Reducing inequalities in care.

• Promoting survivorship.

• Supporting international collaboration.

• Amplifying the global patient voice.

 

By championing these priorities, IKCC contributes to healthcare systems that place patients and families at the centre of kidney cancer care.

​

Empowering Patients Through Education

​

Knowledge is one of the most powerful tools available to anyone affected by cancer. Understanding a diagnosis, available treatments, potential side effects, clinical trials, and long-term follow-up enables patients and families to participate more confidently in discussions with their healthcare teams and make informed decisions throughout their care.

​

Education has therefore become one of the International Kidney Cancer Coalition's core priorities. Working alongside member organisations and medical experts, IKCC promotes the development of reliable, accessible, evidence-based educational resources that help patients better understand kidney cancer and navigate increasingly complex treatment pathways.

​

The Coalition encourages educational resources covering topics such as:

​

• Kidney cancer biology.

• Diagnostic investigations.

• Tumour staging.

• Surgery.

• Systemic therapies.

• Immunotherapy.

• Targeted therapies.

• Clinical trials.

• Side-effect management.

• Nutrition.

• Mental health.

• Survivorship.

• Patient rights.

• Shared decision-making.

 

Although treatment pathways differ significantly for Wilms tumor, the importance of patient education remains exactly the same. Parents of children with Wilms tumor often face unfamiliar medical terminology and complex treatment decisions within a very short period of time. Access to clear, evidence-based educational resources helps reduce uncertainty while enabling families to become active participants in their child's care.

​

The Wilms Cancer Foundation complements this work by developing specialist educational resources dedicated exclusively to Wilms tumor, translating complex medical evidence into practical guidance for families, healthcare professionals, students, and researchers around the world.

​

Supporting Shared Decision-Making

​

Modern healthcare increasingly recognises that patients and families should be active partners in medical decision-making. Rather than simply receiving information, individuals affected by cancer are encouraged to work collaboratively with their healthcare teams when considering treatment options, balancing benefits and risks, and planning ongoing care.

​

IKCC strongly supports this patient-centred model by encouraging healthcare professionals to provide clear, understandable information that enables meaningful conversations and informed choices. Shared decision-making has been shown to improve patient satisfaction, strengthen trust, enhance communication, and support better engagement throughout treatment.

​

For children diagnosed with Wilms tumor, parents and caregivers naturally assume this role on behalf of their child. Access to accurate information and open communication with healthcare professionals enables families to understand treatment recommendations, prepare for surgery or chemotherapy, manage side effects, and participate confidently in discussions regarding long-term follow-up and survivorship.

​

By promoting informed participation, IKCC helps strengthen partnerships between healthcare professionals, patients, and families while reinforcing the principle that excellent healthcare depends upon collaboration as well as clinical expertise.

​

Research, Clinical Trials and International Collaboration

​

Scientific research has transformed kidney cancer care over recent decades, leading to significant advances in diagnosis, surgical techniques, systemic therapies, immunotherapy, precision medicine, and supportive care. IKCC actively supports these advances by encouraging collaboration between researchers, clinicians, patient organisations, and industry partners while promoting patient involvement throughout the research process.

​

The Coalition recognises that patients provide valuable perspectives that can improve research design, identify meaningful outcomes, and ensure that future studies address issues that matter most to people living with kidney cancer.

​

Areas supported by IKCC include:

​

• Patient-centred research.

• Clinical trial awareness.

• Precision medicine.

• Biomarker research.

• Genomic medicine.

• Artificial intelligence.

• Real-world evidence.

• Quality-of-life research.

• Survivorship studies.

• International data sharing.

 

Although Wilms tumor research is conducted through pediatric oncology organisations such as SIOP and the Children's Oncology Group (COG), many broader developments—including precision medicine, genomics, artificial intelligence, imaging, patient-reported outcomes, and survivorship research—have relevance across both adult and pediatric kidney cancers. Continued dialogue between these communities encourages innovation and accelerates the translation of new knowledge into improved patient care.

​

Patient Engagement in Research

​

Increasingly, international research programmes recognise that patients should not simply participate in research—they should help shape it.

IKCC actively promotes meaningful patient involvement throughout the research process, encouraging patients and advocacy organisations to contribute to research priorities, study design, patient information materials, outcome measures, and dissemination of results.

​

This approach helps ensure that research reflects the real-world experiences and priorities of patients rather than focusing exclusively on clinical outcomes.

For families affected by Wilms tumor, similar principles are becoming increasingly important. Parents and survivors can provide valuable insight into quality of life, survivorship, fertility, education, emotional wellbeing, treatment burden, and healthcare navigation. These perspectives help researchers develop studies that address both medical and family-centred outcomes.

​

Global Awareness and Public Education

​

Public awareness remains an essential component of improving kidney cancer outcomes. Earlier recognition of symptoms, timely referral to specialist care, increased understanding of treatment options, and better public knowledge all contribute to improved patient experiences.

​

IKCC supports global awareness initiatives that encourage education among patients, healthcare professionals, policymakers, and the general public. Through international campaigns, educational events, digital resources, webinars, publications, and partnerships with member organisations, the Coalition works to improve understanding of kidney cancer while reducing stigma and misinformation.

​

Although awareness campaigns for adult kidney cancer differ from those for Wilms tumor, the underlying objective remains the same: helping more people recognise potential warning signs, seek appropriate medical attention promptly, and access specialist care without unnecessary delay.

​

The Wilms Cancer Foundation shares this commitment through its own awareness programmes, educational campaigns, multilingual publications, digital learning platforms, conference presentations, and global initiatives focused specifically on childhood kidney cancer. Together, these complementary efforts strengthen awareness across the entire kidney cancer community while recognising the distinct needs of both pediatric and adult patients.

​

The Wilms Cancer Foundation's Contribution

​

The Wilms Cancer Foundation believes that meaningful progress in kidney cancer care depends upon collaboration across the entire kidney cancer community.

​

Although the Foundation specialises exclusively in Wilms tumor, it shares many of the same values promoted by the International Kidney Cancer Coalition, including patient education, evidence-based information, international collaboration, health equity, survivorship, healthcare professional engagement, and patient empowerment.

​

Through initiatives including the Global Wilms Tumor Initiative™ (GWTI), the Wilms Tumor Knowledge Index™ (WTKI), the Wilms Tumor WebApp, multilingual educational resources, international webinars, conference participation, and healthcare professional education, the Foundation contributes specialist expertise that complements IKCC's broader international mission.

​

By strengthening connections between pediatric and adult kidney cancer communities, organisations such as IKCC and the Wilms Cancer Foundation create opportunities to share knowledge, encourage innovation, and promote patient-centred care that benefits people affected by kidney cancer throughout every stage of life.

​

The Wilms Cancer Foundation's Contribution

​

The Wilms Cancer Foundation (WCF) is proud to be a member of the International Kidney Cancer Coalition (IKCC), joining a worldwide alliance of patient organizations committed to improving outcomes for people affected by kidney cancer through advocacy, education, research collaboration, and international partnership.

​

Within this global network, the Wilms Cancer Foundation occupies a unique position as the only international patient organization dedicated exclusively to pediatric renal (kidney) cancer. While many IKCC member organizations focus primarily on adult kidney cancers, particularly renal cell carcinoma (RCC), the Foundation's specialist mission is to improve outcomes for children diagnosed with Wilms tumor (nephroblastoma) and other rare pediatric renal cancers through education, family support, healthcare professional engagement, advocacy, and international collaboration.

​

As a member of IKCC, the Foundation contributes a pediatric perspective to the wider global kidney cancer community, helping to ensure that the unique needs of children, survivors, families, and pediatric healthcare professionals are represented alongside those of the adult kidney cancer community. This complementary relationship strengthens opportunities for shared learning in areas such as patient advocacy, survivorship, health equity, precision medicine, genomics, psychosocial care, digital health, and international policy development.

​

The Foundation advances this work through several flagship initiatives, including:

​

• Global Wilms Tumor Initiative™ (GWTI) – A worldwide programme supporting awareness, education, advocacy, and international collaboration for Wilms tumor.

• Wilms Tumor Knowledge Index™ (WTKI) – One of the world's most comprehensive digital knowledge resources dedicated exclusively to Wilms tumor.

• Wilms Tumor WebApp – A global digital platform providing evidence-based educational resources for families and healthcare professionals.

• Multilingual educational programmes – Expanding access to trusted Wilms tumor information for families and clinicians around the world.

• International partnerships – Collaborating with leading organisations, healthcare professionals, researchers, and advocacy groups to improve outcomes for children with kidney cancer.

 

By bringing specialist expertise in pediatric kidney cancer into the broader international kidney cancer community, the Wilms Cancer Foundation helps bridge the gap between pediatric and adult renal oncology. Together with fellow IKCC member organizations, it contributes to a more comprehensive global approach to kidney cancer—one that recognises the differing needs of children and adults while promoting collaboration, knowledge sharing, innovation, and equitable access to high-quality care for all people affected by kidney cancer.

​

​

International Collaboration, Global Health Equity & the Future of Kidney Cancer Care

​

Building International Partnerships to Improve Kidney Cancer Care

​

Kidney cancer is a global health challenge that extends beyond national borders. While healthcare systems, treatment pathways, and access to specialist services vary considerably between countries, many of the challenges experienced by patients and families are shared worldwide. Improving outcomes therefore requires international collaboration between patient organizations, healthcare professionals, researchers, policymakers, governments, industry, and charitable organizations.

​

The International Kidney Cancer Coalition (IKCC) was established on the principle that collaboration is one of the most effective ways to accelerate progress. By bringing together patient organizations from around the world, the Coalition enables the sharing of knowledge, best practices, educational resources, research priorities, and advocacy strategies that can strengthen kidney cancer care internationally.

​

These partnerships also provide opportunities to identify common barriers to care, develop patient-centred solutions, and encourage greater consistency in healthcare delivery. By fostering collaboration rather than duplication, IKCC helps create a stronger global kidney cancer community that benefits patients regardless of where they live.

​

For children diagnosed with Wilms tumor, this collaborative approach reinforces an important principle: although pediatric and adult kidney cancers are biologically different diseases, many of the wider healthcare challenges—including patient advocacy, health equity, survivorship, education, and international cooperation—are shared. Working together across the wider renal oncology community creates opportunities to improve care for patients of every age.

​

Working Alongside Healthcare Professionals and Researchers

​

One of IKCC's greatest strengths is its ability to bring the patient voice into conversations traditionally led by clinicians, scientists, and healthcare policymakers. Modern cancer care increasingly recognises that patients and families are essential partners in improving healthcare systems, designing research, evaluating treatments, and measuring outcomes.

​

The Coalition encourages close collaboration between patient organizations and:

​

• Medical oncologists.

• Urologists.

• Pediatric oncologists.

• Renal surgeons.

• Oncology nurses.

• Radiologists.

• Pathologists.

• Researchers.

• Clinical trial investigators.

• Allied healthcare professionals.

• Healthcare administrators.

• Government agencies.

 

By strengthening communication between these groups, IKCC promotes healthcare that is scientifically rigorous while remaining responsive to the practical needs of patients and families.

​

Although Wilms tumor is primarily managed through specialist pediatric oncology centres, many broader developments in renal oncology—including advances in imaging, pathology, molecular diagnostics, precision medicine, survivorship research, and patient engagement—continue to influence the wider kidney cancer community. Collaboration across disciplines encourages innovation while supporting continuous improvements in patient care.

​

Promoting Global Health Equity

​

Access to high-quality kidney cancer care remains uneven across the world. While patients in some countries benefit from highly specialised multidisciplinary teams, advanced diagnostic technologies, precision medicine, clinical trials, and comprehensive survivorship services, many others continue to experience significant barriers to diagnosis and treatment.

​

IKCC advocates for a future in which access to quality kidney cancer care is determined by clinical need rather than geography, healthcare infrastructure, or socioeconomic status.

​

Achieving health equity requires improvements across the entire patient pathway, including:

​

• Public awareness.

• Earlier diagnosis.

• Access to specialist centres.

• Multidisciplinary care.

• Modern diagnostic services.

• Evidence-based treatment.

• Clinical trial access.

• Patient education.

• Psychosocial support.

• Survivorship care.

• Rehabilitation.

• Long-term follow-up.

 

These priorities closely align with the broader goals of improving kidney cancer outcomes worldwide and provide valuable principles that are equally applicable to pediatric renal cancers such as Wilms tumor.

​

Supporting Low- and Middle-Income Countries

​

The burden of kidney cancer differs significantly between regions of the world, with healthcare infrastructure, workforce capacity, diagnostic resources, and access to treatment varying widely. Although IKCC's activities primarily focus on patient advocacy rather than direct healthcare delivery, the Coalition recognises the importance of supporting organisations working to improve care in underserved regions.

​

Many patient organisations within the Coalition contribute by:

​

• Raising public awareness.

• Supporting patient education.

• Advocating for improved healthcare services.

• Encouraging earlier diagnosis.

• Promoting equitable access to treatment.

• Sharing educational resources.

• Supporting international research collaboration.

• Reducing disparities in outcomes.

 

These objectives are particularly relevant in low- and middle-income countries, where delays in diagnosis and unequal access to specialist services continue to affect outcomes for many forms of kidney cancer.

​

For children with Wilms tumor, similar challenges exist. Earlier recognition of symptoms, timely referral to pediatric oncology centres, completion of treatment, and access to long-term follow-up remain essential components of improving survival and quality of life.

​

The Wilms Cancer Foundation's Role Within the International Kidney Cancer Community

​

The Wilms Cancer Foundation (WCF) is proud to be a member of the International Kidney Cancer Coalition (IKCC), contributing specialist expertise in pediatric renal (kidney) cancer to one of the world's foremost international networks of kidney cancer patient organizations.

​

Within this global alliance, the Foundation holds a unique position as the only international patient organization dedicated exclusively to pediatric renal (kidney) cancer. Its exclusive focus on Wilms tumor enables the Foundation to contribute a perspective that complements the Coalition's broader work in adult kidney cancer, ensuring that the needs of children, families, survivors, and pediatric healthcare professionals are represented within wider discussions relating to kidney cancer advocacy, education, survivorship, and healthcare policy.

​

Through its membership of IKCC, the Foundation contributes to international dialogue on:

​

• Patient education.

• Family-centred care.

• Childhood kidney cancer awareness.

• Survivorship and long-term follow-up.

• Health equity.

• Rare pediatric renal cancers.

• Healthcare professional education.

• International collaboration.

• Digital health innovation.

• Knowledge translation.

• Patient advocacy.

 

The Foundation's flagship programmes—including the Global Wilms Tumor Initiative™ (GWTI), Wilms Tumor Knowledge Index™ (WTKI), Wilms Tumor WebApp, multilingual educational publications, and international educational partnerships—extend these objectives by providing trusted, evidence-based resources specifically designed for children diagnosed with Wilms tumor and the professionals who care for them.

​

By contributing specialist pediatric expertise to the wider kidney cancer community, the Foundation helps strengthen collaboration across renal oncology while ensuring that childhood kidney cancers remain visible within international discussions focused on improving kidney cancer care worldwide.

​

A Shared Vision for the Future

​

Although IKCC and the Wilms Cancer Foundation serve different patient populations, both organisations share a common vision: ensuring that every person affected by kidney cancer receives timely diagnosis, evidence-based treatment, comprehensive supportive care, and opportunities to achieve the best possible quality of life.

​

Both organisations recognise that future progress depends upon continued investment in:

​

• International collaboration.

• Patient-centred healthcare.

• Research and innovation.

• Precision medicine.

• Artificial intelligence.

• Digital health technologies.

• Education and health literacy.

• Survivorship.

• Global health equity.

• Healthcare professional development.

 

Working together across the wider kidney cancer community creates opportunities to accelerate innovation while improving outcomes for patients throughout every stage of life—from infancy through adulthood.

​

Looking Ahead

​

Kidney cancer care is evolving rapidly through advances in molecular biology, precision medicine, artificial intelligence, genomic profiling, digital health, and international collaboration. At the same time, patient organisations are playing an increasingly influential role in shaping healthcare policy, supporting research, improving education, and ensuring that patient experiences remain central to future developments.

​

The International Kidney Cancer Coalition is expected to remain an important leader within this evolving landscape by continuing to unite patient organisations, strengthen international partnerships, and advocate for equitable access to high-quality kidney cancer care worldwide.

​

As a member of IKCC and the only international organisation dedicated exclusively to pediatric renal (kidney) cancer, the Wilms Cancer Foundation is committed to contributing to this shared vision. By combining specialist expertise in Wilms tumor with global collaboration, digital innovation, multilingual education, healthcare professional engagement, and family support, the Foundation aims to help bridge the gap between pediatric and adult kidney cancer communities while ensuring that children affected by kidney cancer remain visible within the international renal oncology agenda.

​

Together, IKCC and its member organisations demonstrate that meaningful progress is achieved not by working in isolation, but by sharing knowledge, supporting one another, and collaborating across disciplines, countries, and healthcare systems to improve outcomes for everyone affected by kidney cancer.